FGFR fusions in the driver's seat

Cancer Discovery

Volumn 3, Issue 6, 2013, Pages 607-609

  Sabnis, Amit J ^a,b   Bivona, Trever G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3, 5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO) PYRIDO [2, 3 D] PYRIMIDIN 7 YL] UREA; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; AZD 4547; BCR ABL PROTEIN; BGJ 398; CRIZOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; ONCOPROTEIN; PAZOPANIB; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; ENDOMETRIUM CANCER; GERM LINE GENE THERAPY; GLIOBLASTOMA; HUMAN; LUNG ADENOCARCINOMA; MYELOPROLIFERATIVE NEOPLASM; NEOPLASM; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; RHABDOMYOSARCOMA; RNA ISOLATION; RNA SEQUENCE; UTERINE CERVIX CANCER;

HUMANS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84878872190     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0185     Document Type: Article

References (10)

1. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011;17:297-303.
2. Wu Y-M, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identifi cation of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.
3. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, etal. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-5.
6. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
7. Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/ lymphoma syndrome. Nat Genet 1998;18:84-7.
8. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3:264-79.
9. Taylor J Gt, Cheuk A T, Tsang PS, Chung JY, Song YK, Desai K, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009;119:3395-407.
10. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012;18:3780-90.